Sexually transmitted diseases
May 25, 2026 · via Europe PMC
Temporal Trends in Anal HPV Infection Among Men Who Have Sex With Men Attending Sexual Health Clinics in Three United States Cities, 2018-2024.
DeSisto CL, Querec TD, Winer RL, +5 more, Markowitz LE.
AI summary — for doctors, generated from the abstract only
Anal HPV vaccine-type prevalence fell among US men who have sex with men without HIV from 2018 to 2024 while non-vaccine types stayed flat, consistent with a vaccine effect.
What was studied
Serial testing of residual anal specimens from MSM aged 18-45 without HIV at sexual health clinics in three US cities for 28 HPV genotypes, with Joinpoint trend analysis by age group.
Key findings
- In ages 18-26, 4vHPV-type prevalence dropped from 23.7% to 13.4% (APC -13.4%).
- In ages 27-45, it dropped from 37.2% to 28.2% (APC -5.6%).
- Non-vaccine-type prevalence was stable or only slightly lower, suggesting unchanged sexual exposure.
Clinical relevance
The results support the value of HPV vaccination for MSM, including beyond the youngest ages, for preventing anal HPV infection.
Who should care
Limitations
Clinic-attending MSM are not representative of all MSM, and vaccination status was not available to link directly to infection.
Recommend and offer HPV vaccination to eligible MSM, including adults up to the age range where it is indicated.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Background
We assessed temporal trends in prevalent anal human papillomavirus (HPV) infection among men who have sex with men (MSM) without HIV who attended sexual health clinics in 3 US cities from 2018 to 2024.
Methods
Residual anal specimens from MSM without HIV, aged 18 to 45 years, were tested for 28 HPV genotypes. Demographic information was obtained from clinic records. Trends in quadrivalent vaccine (4vHPV)-type prevalence and nonvaccine-type HPV prevalence were evaluated using Joinpoint regression, stratified by age group (18-26 and 27-45 years). Nonvaccine-type HPV prevalence was used as a measure of sexual exposure; these HPV types are not targeted by any available vaccine. Joinpoint regression fits a series of joined straight lines on a logarithmic scale to the trends in prevalence; trends were reported as annual percent change (APC).
Results
Among persons aged 18 to 26 years, 4vHPV-type prevalence declined from 23.7% in 2018 to 2019 to 13.4% in 2023 to 2024 (APC = -13.4%), while nonvaccine-type HPV prevalence had a slight but nonsignificant decline. Among persons aged 27 to 45 years, 4vHPV-type prevalence declined from 37.2% in 2018 to 2019 to 28.2% in 2023 to 2024 (APC = -5.6%), while nonvaccine-type HPV prevalence remained stable.
Conclusions
Among MSM aged 18 to 26 and 27 to 45 years, there was a decline in 4vHPV-type prevalent anal infections from 2018 to 2024. There was little to no decline in nonvaccine-type HPV prevalence during the same time period, suggestive of unchanging sexual exposure to HPV. These data demonstrate the impact of HPV vaccine on anal HPV infections in MSM.
DOI
10.1097/olq.0000000000002362
PMID
42183680
PMCID
PMC13271034
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed